Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopure Disclosure Policies To Be Reviewed Under Hemopure SEC Settlement

Executive Summary

Biopure must undergo a review of its disclosure, compliance and other securities policies as part of a settlement with the Securities & Exchange Commission over alleged misrepresentations concerning its investigational synthetic blood product Hemopure

You may also be interested in...



FDA May Use Panels More Often To Evaluate Emergency Research Protocols

FDA is questioning whether protocols for emergency research conducted without individual informed consent should be subjected to more public input

FDA/SEC Cooperation On Investor Communications To Be Headed By Taylor

FDA Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison with the Securities & Exchange Commission as FDA expands its role in regulating investor communications

FDA Investor Relations: SEC Agreement Close, “Complete Response” Reg Not

FDA's role in policing investor communications about regulatory actions will continue to receive attention in 2004 after the Securities & Exchange Commission opened investigations into Biopure and Amylin

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel